A recent study published on January 25, 2022, on JAMA Network, has shown that the risk of myocarditis following mRNA COVID vaccination is around 133 times greater than the background risk in the population.
The study, conducted by researchers from the U.S. Centers for Disease Control (CDC) as well as from several U.S. universities and hospitals, examined the effects of vaccination with products manufactured by Pfizer-BioNTech and Moderna.
The study’s authors used data obtained from the CDC’s VAERS reporting system which were cross-checked to ensure they complied with CDC’s definition of myocarditis; they also noted that given the passive nature of the VAERS system, the number of reported incidents is likely to be an underestimate of the extent of the phenomenon.
1626 cases of myocarditis were studied, and the results showed that the Pfizer-BioNTech product was most associated with higher risk, with 105.9 cases per million doses after the second vaccine shot in the 16 to 17 age group for males, and 70.7 cases per million doses after the second shot in the 12 to 15 age group for males. The 18 to 24 male age group also saw significantly higher rates of myocarditis for both Pfizer’s and Moderna’s products (52.4 and 56.3 cases per million respectively).
Read More: CDC Study finds Covid-19 Vaccination increases risk of suffering Myocarditis by 13,200%
